Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

8.75 EUR

-0.11 %

5,650 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-0.11 %
+7.49 %
-18.22 %
-38.38 %
-40.27 %
+10.48 %
+150.00 %
+78.43 %
-98.56 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
70.66M EUR
Turnover
21.96K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
14.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Research, tools and community to support better investment decisions.

FREE account
The market's most popular morning review
Analysts' recommendations and comments
Stock comparison and the investor discussion forum
PREMIUM account
All company reports and analyses
Premium content: model portfolio, insider transactions, Premium articles
Inderes MCP: Inderes data directly into your AI tools
Create account
Forum discussions
Based on a quick calculation, the shareholdings of eight management team or board members in the top 100 have increased by thousands of shares in May. That, if anything, increases my own confidence in the company’s performance.
10 hours ago
18
Agreed, the vibe is good. Nothing has changed from the 16 prices. Perhaps there was an expectation that Brainlab’s impact would start sooner, leading to some gloominess. In fact, the beginning of the year has gone quite swimmingly, and I believe a good purpose has been planned for...
5/25/2026, 7:59 PM
by Jatast
12
nexstim.com Nexstim - Nexstimin suurimmat osakkeenomistajat Everything is looking very green (positive). Of course, most of the green is related to recent events. It’s great to see the insiders appearing more prominently on the lists.
21 hours ago
by Jatast
11
I have a small speculative position myself, but I don’t view this as the “sure thing” that many here are advertising. The stock price still factors in quite a bit of positivity already. And even though approvals have been secured, devices are in use worldwide, and positive results...
5/26/2026, 1:30 PM
by Gold
11
Perhaps they do not wish to disclose more details at this stage, but the following comment from CEO Karvinen outlines the rough plan: “thereby strengthening the Company’s financial position for the next phases in the execution of our profitable growth strategy.”
5/25/2026, 7:10 PM
10
If we’re going to split hairs here, the majority of those top 100 increasers were certainly not involved in the arrangement made in connection with Eiffel. It could, of course, be related in the sense that the investment and the arrangement have been perceived as a positive thing...
18 hours ago
by Kyhnykeisari
8
Every now and then I wonder why anyone would buy Nexstim when you could buy Brainsway instead. Its share price seems to be chugging steadily upwards, unlike its domestic peer. Over the last year, it’s up +200%.
5/27/2026, 5:31 AM
by JuhaT
7
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.